CBER FDA Letters

The FDA issued a Complete Response Letter (CRL) for Biologics License Application (BLA) 761211 for AEB1102, indicating that the effectiveness of the drug has not been established for traditional approval. While the drug showed a statistically significant reduction in plasma arginine levels, it failed to meet key secondary clinical endpoints. The FDA suggests that plasma arginine may be a reasonably likely surrogate endpoint for accelerated approval, provided a confirmatory trial is conducted. The letter outlines numerous deficiencies related to clinical efficacy, safety data updates, labeling, proprietary name resubmission, and specific clinical and clinical pharmacology data requirements, including trials for pediatric patients and subcutaneous administration.

This document is a letter from the U.S. Food and Drug Administration (FDA) to an applicant regarding Biologics License Application (BLA) 761147. It outlines deficiencies in the application, provides guidance on labeling resources, addresses the proprietary name, and details extensive requirements for a safety update that must be included in the resubmission.

This FDA communication outlines specific requirements for the resubmission of Biologics License Application (BLA) 761303, focusing on updated prescribing information, safety data, and general submission procedures. It emphasizes adherence to labeling regulations and guidance, and mandates the provision of comprehensive safety information from clinical trials and worldwide experience.

This FDA letter outlines deficiencies and requirements for Biologics License Application (BLA) 761385 for the drug TVB-009. It details specific instructions for updating labeling (content, carton, and container), resubmitting the proprietary name, and providing a comprehensive safety update. The letter also acknowledges the proposed Risk Evaluation and Mitigation Strategy (REMS) and sets a one-year deadline for resubmission or other actions.

The U.S. Food & Drug Administration (FDA) issued a Complete Response Letter for Replimune, Inc.'s Biologics License Application (BLA) for vusolimogene oderparepvec. Final approval cannot be granted due to significant clinical deficiencies in the RPL-001-16 and RP1-104 trials, which failed to provide substantial evidence of effectiveness or adequately isolate the drug's contribution, and unaddressed Chemistry, Manufacturing, and Controls (CMC) issues.

The FDA issued a Complete Response Letter for Capricor, Inc.'s Biologics License Application (BLA) for deramiocel, indicating that the application cannot be approved in its current form due to significant deficiencies in clinical data and lack of substantial evidence of effectiveness.

The U.S. Food & Drug Administration (FDA) issued a Complete Response Letter to Ultragenyx Pharmaceutical Inc. for their Biologics License Application (BLA) for rebisufligene etisparvovec. The FDA concluded that final approval cannot be granted due to deficiencies primarily related to Chemistry, Manufacturing, and Controls (CMC) and outstanding clinical data requirements.

This letter from the FDA outlines deficiencies in Biologics License Application (BLA) 761027, requiring the applicant to revise labeling, resubmit the proprietary name, and provide a comprehensive safety update. It also specifies the timeline and format for resubmission.

This FDA letter outlines deficiencies and requirements for the applicant of Biologics License Application (BLA) 761377 to achieve approval. It details specific instructions for submitting revised prescribing information, carton and container labeling, proprietary name information, and a comprehensive safety update. The letter also provides guidance on the resubmission process and timelines.

This FDA letter addresses deficiencies in Biologics License Application (BLA) 761308, providing detailed instructions for revising labeling, updating safety information, and resubmitting the application. It outlines specific requirements for content, format, and timelines to achieve potential approval, emphasizing that the product cannot be marketed until written approval is received.

This FDA letter, identified as BLA 761424, outlines deficiencies in a Biologics License Application and provides detailed instructions for resubmission. It specifies requirements for updating prescribing information (labeling) to conform with regulations and guidances, and mandates a comprehensive safety update incorporating new clinical data, worldwide experience, and foreign labeling translations.

This document is a deficiency letter from the FDA regarding Biologics License Application (BLA) 761393. It outlines deficiencies related to product quality, prescribing information, proprietary name, and requires a comprehensive safety update upon resubmission. The letter also provides instructions for resubmission and potential next steps.

This document is a letter from the U.S. Food and Drug Administration (FDA) to an applicant regarding Biologics License Application (BLA) 761290. It outlines deficiencies and provides instructions for resubmission, including requirements for labeling, proprietary name, and a comprehensive safety update. The letter also specifies the timeline and format for resubmission and notes that the product cannot be marketed until approved.

The FDA has issued a Complete Response letter for Atara Biotherapeutics, Inc.'s Biologics License Application (BLA) for tabelecleucel, indicating that final approval cannot be granted due to unresolved deficiencies related to Chemistry, Manufacturing, and Controls (CMC) and inspectional observations. The FDA reserves comment on labeling until other issues are resolved.

This document outlines specific requirements and recommendations for a Biologics License Application (BLA) for a biosimilar product, focusing on the submission of updated safety data, labeling information, and proprietary name details. It emphasizes compliance with FDA regulations and guidance for biosimilar products.

This FDA letter outlines deficiencies and requirements for the resubmission of Biologics License Application (BLA) 761433, providing instructions for updated labeling, clinical data, safety information, and product quality assessments.

This document is a deficiency letter from the FDA regarding Biologics License Application (BLA) 761271. It outlines several deficiencies and required actions related to facility inspection, labeling, proprietary name, and a comprehensive safety update, which must be addressed for the application to be approved.

This letter from the FDA outlines deficiencies in a Biologics License Application (BLA) for a biosimilar product, providing specific instructions for a safety update, proprietary name resubmission, and general resubmission procedures to achieve approval.

This document is a deficiency letter from the FDA regarding Biologics License Application (BLA) 761147. It addresses proposed labeling, proprietary name, and outlines detailed requirements for a safety update, including specific data presentation and analysis. It also provides instructions for resubmission and potential consequences of inaction.

This document is a deficiency letter from the U.S. Food and Drug Administration (FDA) regarding Biologics License Applications (BLA) 761326/Original 1 and 761326/Original 2. It outlines deficiencies found during facility inspections, clinical data review (specifically for BLA 761326/Original 1 concerning glycemic control in type 1 diabetes), and provides instructions for addressing prescribing information, proprietary name, and safety updates. The letter also specifies actions required within one year for resubmission or other regulatory actions.

This letter from the FDA addresses deficiencies in Biologics License Application (BLA) 761377, requesting specific updates and submissions related to labeling, proprietary name, and a comprehensive safety update. It outlines the requirements for resubmission and the timeline for action.

This document is a Complete Response Letter (CRL) from the FDA for Biologics License Application (BLA) 761366, detailing deficiencies that must be addressed before the application can be approved. It outlines specific requirements for labeling revisions, proprietary name resubmission, and a comprehensive safety update, along with instructions for resubmission or other actions.

This is a Complete Response Letter from the FDA to Rocket Pharmaceuticals, Inc. regarding their Biologics License Application (BLA) for marnetegragene autotemcel. The FDA has concluded that they cannot grant final approval due to deficiencies, primarily in Chemistry, Manufacturing, and Controls (CMC), and also reserves comment on labeling until the application is otherwise acceptable. The letter outlines requirements for resubmission and options for discussion.

This document is a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) to an applicant regarding Biologics License Application (BLA) 761308. It outlines deficiencies found in the application and specifies additional information and actions required for potential approval, particularly focusing on safety data, clinical trial information, and administrative procedures for resubmission.

This FDA letter, pertaining to Biologics License Application (BLA) 761187, outlines deficiencies and requirements for the applicant to address. It covers aspects of prescription drug labeling, carton and container labeling, proprietary name resubmission, and a comprehensive safety update. The letter also provides instructions for resubmission and notes that the product cannot be marketed until approved.

This document is a Complete Response Letter (CRL) from the FDA regarding Biologics License Application (BLA) 761376. It outlines deficiencies that prevent approval and provides instructions for resubmission, including requirements for a safety update, proprietary name resubmission, and labeling considerations. Several sections detailing product quality, microbiology, drug substance, and drug product deficiencies are redacted.

This document is a deficiency letter from the FDA regarding Biologics License Application (BLA) 761356, outlining specific requirements and recommendations for its resubmission. It addresses deficiencies related to facility inspections, prescribing information, proprietary name, and a comprehensive safety update.

This section provides feedback from the FDA regarding a Biologics License Application (BLA 761147), specifically addressing proposed labeling, proprietary name, and the requirement for a safety update. It encourages the applicant to review relevant FDA resources and guidance documents.

This letter from the FDA addresses deficiencies in a Biologics License Application (BLA 761357) and outlines requirements for its resubmission. It covers facility inspections, prescribing information, proprietary name, and a detailed safety update, emphasizing that the product cannot be marketed until approved.

This letter from the FDA identifies deficiencies in a Biologics License Application (BLA) for a product intended for follicular lymphoma, specifically regarding the timely completion of confirmatory trials. It outlines requirements for resubmission, including addressing trial progress, updating prescribing information and safety data, and resubmitting the proprietary name. The letter also provides instructions for the format and content of the resubmission and sets a one-year deadline for action.

This document is a letter from the U.S. Food and Drug Administration (FDA) to an applicant regarding deficiencies found in their Biologics License Application (BLA) 761303/Original 2. It outlines specific requirements for addressing issues related to clinical trial completion, prescribing information, proprietary name, and safety updates, which must be fulfilled for a successful resubmission. The letter also provides guidance on the resubmission process and timelines.